ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email
Novo Nordisk hikes its 2026 outlook, but investors focus more on quarterly sales of the Danish pharma giant’s Wegovy weight loss pill, which came in slightly lower than expected. CEO Mike Doustdar addresses the expectations in a first on CNBC interview with Carolin Roth.
08:41
Wed, Aug 5 20264:27 AM EDT